Effect of alemtuzumab on fatigue, quality of life, and patient/caregiver-reported outcomes in relapsing-remitting multiple sclerosis-A real-world evidence study.

Background: Alemtuzumab is approved in the European Union for treating highly active relapsing-remitting multiple sclerosis (RRMS). Patient-reported outcomes measure the treatment impact on quality of life (QoL), including fatigue, a common symptom in multiple sclerosis (MS). Chronic diseases like MS also affect the patient's caregiver.

Predicting Epileptic Seizures Using Biometric Sensors - A Pilot Study Protocol.

Epilepsy is a prevalent neurological disorder characterized by unpredictable seizures despite some known risk factors. Using an mHealth system and Empatica EmbracePlus, we aim to examine if biometric sensor data can detect and predict epileptic seizures. Five participants with epilepsy will be followed for a minimum of 15 seizures.

Towards Automatic Migraine-Event Prediction Using Continuous Sensor Data.

Migraine is a chronic headache disorder. A prototype mobile app-based system was implemented to test data collection and improve data coverage for the Empatica E4 biometric sensor device. Results from the prototype testing are reported.

Educational patterning in biological health seven years apart: Findings from the Tromsø Study.

Background: Social-to-biological processes is one set of mechanisms underlying the relationship between social position and health. However, very few studies have focused on the relationship between social factors and biology at multiple time points. This work investigates the relationship between education and the dynamic changes in a composite Biological Health Score (BHS) using two time points seven years apart in a Norwegian adult population.

Impact of extent of resection on outcome from glioblastoma using the RANO resect group classification system: a retrospective, population-based cohort study.

Background: Extent of resection (EOR) is associated with survival in glioblastoma. A standardized classification for EOR was lacking until a system was recently proposed by the response assessment in neuro-oncology (RANO) resect group. We aimed to assess EOR in an unselected glioblastoma cohort and use this classification system to evaluate the impact on survival in a real-world setting.